JPRN-UMIN000009585
Not yet recruiting
Phase 3
Phase III study to clarify the efficacy and safety of aprepitant or palonosetron on chemotherapy with paclitaxel and carboplatin for gynecologic cancer - Phase III study to clarify the efficacy and safety of aprepitant or palonosetron on chemotherapy with paclitaxel and carboplatin for gynecologic cancer
Obstetrics and Gynecology, Tokushima University Hospital0 sites100 target enrollmentMarch 1, 2013
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Obstetrics and Gynecology, Tokushima University Hospital
- Enrollment
- 100
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Past history of previous chemotherapy 2\. Hypersensitivity for Aprepitant or Palonosetron
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Phase III study for evaluating efficacy and safety of desensitization based on IDEC-C2B8 in living donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody. Phase III study for evaluating efficacy, safety and pharmacokinetics of pre-transplant administration of FK506 or FK506E(MR4) for 7 to 28 days in living donor kidney transplantation recipients.iving donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody.JPRN-jRCT2080224107ZENYAKU KOGYO CO., LTD.23
Completed
Phase 3
Phase III study for evaluating efficacy and safety of a combination treatment of IDEC-C2B8 with steroid pulse therapy and plasmapheresis for antibody-mediated rejection after kidney transplant.JPRN-jRCT2080224105ZENYAKU KOGYO CO., LTD.20
Active, not recruiting
Phase 1
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableAtopic dermatitisMedDRA version: 18.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-002653-35-IERegeneron Pharmaceuticals, Inc.330
Active, not recruiting
Phase 1
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableAtopic dermatitisMedDRA version: 19.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-002653-35-DERegeneron Pharmaceuticals, Inc.330
Active, not recruiting
Phase 1
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableAtopic dermatitisMedDRA version: 19.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-002653-35-BERegeneron Pharmaceuticals, Inc.330